Seroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous community

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorVASCONCELOS, Mariana Pinheiro Alves
dc.contributor.authorSANCHEZ-ARCILA, Juan Camilo
dc.contributor.authorPERES, Luciana
dc.contributor.authorSOUSA, Paulo Sergio Fonseca de
dc.contributor.authorCASTRO-ALVES, Julio
dc.contributor.authorALBUQUERQUE, Hermano Gomes
dc.contributor.authorMENDES-CORREA, Maria Cassia
dc.contributor.authorMAIA-HERZOG, Marilza
dc.contributor.authorLEWIS-XIMENEZ, Lia Laura
dc.contributor.authorVILLAR, Livia Melo
dc.contributor.authorOLIVEIRA-FERREIRA, Joseli
dc.date.accessioned2024-02-15T14:47:45Z
dc.date.available2024-02-15T14:47:45Z
dc.date.issued2024
dc.description.abstractBackground Viral hepatitis is a significant health concern among indigenous population in the Americas. In Brazil, reports find high endemicity of HBV and HDV infections has been reported in several indigenous groups. However, few studies have documented the prevalence of HBV, HCV and HDV in the Yanomami. In this study, the prevalence of hepatitis B, C, and D serological markers and potential risk factors were investigated to provide guidance for the development of strategies aimed at reducing viral transmission in the Yanomami indigenous villages.Methods This cross-sectional study was carried out in March 2015 and included 430 individuals from four Yanomami villages: Alapusi (n = 78), Castanha/Ahima (n = 126), Gasolina (n = 105), and Taibrapa (n = 121). A rapid test was used for detection of HBsAg and anti-HCV and chemiluminescent immunoassay for anti-HBs, anti-HBc, and anti-HDV antibodies.Results HBsAg, anti-HBc, and anti-HBs were detected in 8.8, 45.5, and 49.4% of the participants, respectively. The estimated HBV status: current infection 9.6% (38/395); resolved infection 43.3% (171/395); vaccine immunity 20.5% (81/395), and susceptible to HBV 26.6% (105/395). Gasolina presented the lowest prevalence of HBV infection (6.5%) and the highest prevalence of vaccine immunity (26.9%). Children < 15 years old were highly susceptible to infection, as 53.1% did not have antibodies to HBV, while more than 80% of individuals over 45 years of age had been exposed to HBV. The markers for HDV were founded among 12.5% (4/32) of the HBsAg carriers. Anti-HCV was identified in all villages, with the highest prevalence in Alapusi (5.1%). Possible risk factors such as the use of piercings, tattoos, and contact with prospectors showed no statistical difference between the groups.Conclusions Viral hepatitis B and serological markers for HCV and HDV were found to be widely distributed among the Yanomami indigenous community, while the prevalence of vaccine immunity to HBV was low. This finding reinforces the importance of promoting systematized diagnostic and vaccination strategies in indigenous communities. Our data confirm that isolated and difficult-to-reach indigenous communities lack appropriate access to diagnosis, treatment, and vaccination.eng
dc.description.indexMEDLINE
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus
dc.description.sponsorshipInstituto Oswaldo Cruz -IOC/ FIOCRUZ
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq [479559/2013, 308424/2022-0]
dc.description.sponsorshipCoordenaco de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]
dc.description.sponsorshipPAEF/ FIOCRUZ [IOC-008-FIO-22-2-49]
dc.description.sponsorshipFAPERJ - Fundaco de Amparo a Pesquisa do Estado do Rio de Janeiro [E-26/203.133/2019, E-26/ 200.938/2022]
dc.identifier.citationBMC INFECTIOUS DISEASES, v.24, n.1, article ID 15, 10p, 2024
dc.identifier.doi10.1186/s12879-023-08928-z
dc.identifier.eissn1471-2334
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/57946
dc.language.isoeng
dc.publisherBMCeng
dc.relation.ispartofBMC Infectious Diseases
dc.rightsopenAccesseng
dc.rights.holderCopyright BMCeng
dc.subjectViral hepatitiseng
dc.subjectHBVeng
dc.subjectHDVeng
dc.subjectHCVeng
dc.subjectYanomamieng
dc.subject.otherviruseng
dc.subject.otherstateeng
dc.subject.otherepidemiologyeng
dc.subject.otherpopulationseng
dc.subject.otherprevalenceeng
dc.subject.otherinfectioneng
dc.subject.wosInfectious Diseaseseng
dc.titleSeroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous communityeng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalVASCONCELOS, Mariana Pinheiro Alves:Ctr Med Trop Rondonia CEMETRON, Porto Velho, RO, Brazil; Fiocruz MS, Lab Imunoparasitol, Inst Oswaldo Cruz IOC, Rio De Janeiro, RJ, Brazil
hcfmusp.author.externalSANCHEZ-ARCILA, Juan Camilo:Fiocruz MS, Lab Imunoparasitol, Inst Oswaldo Cruz IOC, Rio De Janeiro, RJ, Brazil
hcfmusp.author.externalPERES, Luciana:Fiocruz MS, Inst Oswaldo Cruz IOC, Lab Hepatites Virais, Rio De Janeiro, Brazil
hcfmusp.author.externalSOUSA, Paulo Sergio Fonseca de:Fiocruz MS, Inst Oswaldo Cruz IOC, Lab Hepatites Virais, Rio De Janeiro, Brazil
hcfmusp.author.externalCASTRO-ALVES, Julio:Fundacao Oswaldo Cruz FIOCRUZ, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil
hcfmusp.author.externalALBUQUERQUE, Hermano Gomes:Fiocruz MS, Lab Doencas Parasitarias, Inst Oswaldo Cruz IOC, Rio De Janeiro, Brazil
hcfmusp.author.externalMAIA-HERZOG, Marilza:Fiocruz MS, Colecao Simulideos Inst Oswaldo Cruz IOC, Lab Referencia Nacl Simulideos Oncocercose & Manso, Rio De Janeiro, Brazil
hcfmusp.author.externalLEWIS-XIMENEZ, Lia Laura:Fiocruz MS, Inst Oswaldo Cruz IOC, Lab Hepatites Virais, Rio De Janeiro, Brazil
hcfmusp.author.externalVILLAR, Livia Melo:Fiocruz MS, Inst Oswaldo Cruz IOC, Lab Hepatites Virais, Rio De Janeiro, Brazil
hcfmusp.author.externalOLIVEIRA-FERREIRA, Joseli:Fiocruz MS, Lab Imunoparasitol, Inst Oswaldo Cruz IOC, Rio De Janeiro, RJ, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcMARIA CASSIA JACINTHO MENDES CORREA
hcfmusp.description.articlenumber15
hcfmusp.description.issue1
hcfmusp.description.volume24
hcfmusp.origemWOS
hcfmusp.origem.pubmed38166687
hcfmusp.origem.scopus2-s2.0-85181245480
hcfmusp.origem.wosWOS:001135345000003
hcfmusp.publisher.cityLONDONeng
hcfmusp.publisher.countryENGLANDeng
hcfmusp.relation.referenceAASLD-IDSA Hepatitis C Guidance, 2020, HEPATOLOGY, V71, P686, DOI 10.1002/hep.31060eng
hcfmusp.relation.referenceAguiar José Ivan, 2002, Braz J Infect Dis, V6, P269, DOI 10.1590/S1413-86702002000500010eng
hcfmusp.relation.referenceAlbert B., 2009, Uhiri A: a terra-floresta Yanomamieng
hcfmusp.relation.referenceDias ALB, 2012, REV SOC BRAS MED TRO, V45, P9, DOI 10.1590/S0037-86822012000100003eng
hcfmusp.relation.referenceBlach S, 2022, LANCET GASTROENTEROL, V7, P396, DOI 10.1016/S2468-1253(21)00472-6eng
hcfmusp.relation.referenceBlanco RY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197662eng
hcfmusp.relation.referenceBraga W S, 2001, Rev Soc Bras Med Trop, V34, P349, DOI 10.1590/S0037-86822001000400007eng
hcfmusp.relation.referenceBraga WSM., 2004, Epidemiol Serv Saude, V13, P35, DOI 10.5123/S1679-49742004000100005eng
hcfmusp.relation.referenceBraga WSM., 2004, J Braz Soc Trop Med, V37, P9, DOI [10.1590/S0037-86822004000700002, DOI 10.1590/S0037-86822004000700002]eng
hcfmusp.relation.referenceBrasil, 2019, Saude indigena: analise da situacao de saude no SasiSUSeng
hcfmusp.relation.referenceBrasil, 2022, Boletim Epidemiologico de Hepatites Virais 2022eng
hcfmusp.relation.referenceBrasil, 2013, Nota tecnica conjunta 02/2013/CGPNI/DEVEP e CGDHRV/DST-AIDS/SVS/MSeng
hcfmusp.relation.referenceCoimbra CEA, 1996, SOC SCI MED, V42, P1735, DOI 10.1016/0277-9536(95)00295-2eng
hcfmusp.relation.referenceConners Erin E, 2023, MMWR Recomm Rep, V72, P1, DOI 10.15585/mmwr.rr7201a1eng
hcfmusp.relation.referenceda Costa CA, 2012, REV SOC BRAS MED TRO, V45, P457, DOI 10.1590/S0037-86822012000400008eng
hcfmusp.relation.referenceDuarte MC, 2010, TROP MED INT HEALTH, V15, P924, DOI 10.1111/j.1365-3156.2010.02560.xeng
hcfmusp.relation.referenceFarci P, 2012, SEMIN LIVER DIS, V32, P228, DOI 10.1055/s-0032-1323628eng
hcfmusp.relation.referenceFerraz ML, 2020, BRAZ J INFECT DIS, V24, P434, DOI 10.1016/j.bjid.2020.07.012eng
hcfmusp.relation.referenceFigueiredo JO., 2016, Hepatite B e D na area do Distrito Sanitario Especial Indigena do Alto Rio Solimoes-aspectos associados a prevalencia e ao programa de atendimento aos portadores [dissertacao]eng
hcfmusp.relation.referenceFONSECA JCF, 1988, T ROY SOC TROP MED H, V82, P469, DOI 10.1016/0035-9203(88)90166-6eng
hcfmusp.relation.referenceFreitas N, 2012, HEPATOLOGY, V56, P76, DOI 10.1002/hep.25663eng
hcfmusp.relation.referenceGarcia HM, 2022, J PEDIATR NURS, V65, pE1, DOI 10.1016/j.pedn.2021.11.024eng
hcfmusp.relation.referenceIBGE, 2012, Censo 2010: populacao indigena e de 896,9 mil, tem 305 etnias e fala 274 idiomaseng
hcfmusp.relation.referenceKomatsu H, 2020, HEPATOL RES, V50, P272, DOI 10.1111/hepr.13470eng
hcfmusp.relation.referenceMacLachlan JH, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021410eng
hcfmusp.relation.referenceNunes HM, 2007, CAD SAUDE PUBLICA, V23, P2756, DOI 10.1590/S0102-311X2007001100023eng
hcfmusp.relation.referenceNunes HM., 2016, Revista Pan-Amazonica de Saude, V7, P71, DOI [10.5123/S2176-62232016000500008, DOI 10.5123/S2176-62232016000500008]eng
hcfmusp.relation.referenceRazavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6eng
hcfmusp.relation.referenceStockdale AJ, 2020, J HEPATOL, V73, P523, DOI 10.1016/j.jhep.2020.04.008eng
hcfmusp.relation.referenceTORRES JR, 1991, REV INFECT DIS, V13, P52eng
hcfmusp.relation.referenceTorres JR, 1996, GUT, V38, pS48, DOI 10.1136/gut.38.Suppl_2.S48eng
hcfmusp.relation.referenceVerso MG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030467eng
hcfmusp.relation.referenceVerso MG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010001eng
hcfmusp.relation.referenceVillar LM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3279-2eng
hcfmusp.relation.referenceWHO, 2022, Hepatitis Deng
hcfmusp.relation.referenceWHO, 2022, Hepatitis Ceng
hcfmusp.relation.referenceWorld Health Organization, 2022, HEP Beng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication4ec4044d-75d1-4d30-8176-efd04b22c8d6
relation.isAuthorOfPublication.latestForDiscovery4ec4044d-75d1-4d30-8176-efd04b22c8d6
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03